<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02625233</url>
  </required_header>
  <id_info>
    <org_study_id>CR-5788</org_study_id>
    <nct_id>NCT02625233</nct_id>
  </id_info>
  <brief_title>Clinical Long-Term Evaluation of Approved and Investigational Contact Lenses</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-site, dispensing, 4-visit, 2-arm parallel group, randomized, double-masked
      clinical trial using a Vistakon investigational contact lens (test) and a marketed monthly
      replacement contact lens (control). Each subject will be assigned randomly to either the test
      or control lens to evaluate the long term safety and efficacy of the investigational contact
      lens compared to the marketed contact lens over a period of six months of lens wear.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2015</start_date>
  <completion_date type="Actual">February 1, 2016</completion_date>
  <primary_completion_date type="Actual">February 1, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Eyes Grade 3 or Higher SLF</measure>
    <time_frame>Up to 6 Month Follow-up</time_frame>
    <description>Slit lamp findings were graded using a FDA Grade Scale, 0 = None, 1 = Slight, 2 = Moderate, 3 = Significant, 4 = Advanced. Measurements were taken in each subject eye at the initial visit, 4 month, 5 month and 6 month follow-up evaluations. This study is a continuation of a previous study therefore data from the initial visit was included in reporting. The proportion of subject eyes with SLF grade 3 or higher was reported for each lens.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Acuity (logMAR)</measure>
    <time_frame>Up to 6 Month Follow-up</time_frame>
    <description>The visual acuity (LogMAR) was collected at the initial visit, 4 month, 5 month and 6 month follow-up evaluations. This study is a continuation of a previous study therefore data from the initial visit was included in reporting. The average Visual Acuity (logMAR) across the 4 study visits and at each individual visit was reported for each lens.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Visual Disorders</condition>
  <arm_group>
    <arm_group_label>senofilcon C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vistakon Investigational Contact Lens (Test)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>comfilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Marketed Monthly Wear Contact Lens (Control)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>senofilcon C</intervention_name>
    <arm_group_label>senofilcon C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>comfilcon A</intervention_name>
    <arm_group_label>comfilcon A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and
             receive a fully executed copy of the form.

          -  The subject must appear able and willing to adhere to the instructions set forth in
             this clinical protocol.

          -  The subject must be at least 18 years of age.

          -  The subject's vertex corrected spherical equivalent distance refraction must be in the
             range of -1.00 to -6.00 in each eye.

          -  The subject's refractive cylinder must be ≤ 1.00 Diopters (D) in each eye.

          -  The subject must have best corrected visual acuity of 20/25 or better in each eye.

          -  The subject should own a wearable pair of spectacles and bring to initial visit.

          -  The subject must be an adapted frequent replacement daily wear spherical silicone
             hydrogel soft contact lens wearer in both eyes.

          -  The subject must have normal eyes (i.e., no ocular medications or infections of any
             type).

          -  The subject must have enrolled and completed all visits in clinical study
             (NCT02515994).

        Exclusion Criteria:

          -  Currently pregnant or lactating (subjects who become pregnant during the study will be
             discontinued).

          -  Any systemic disease, autoimmune disease, or use of medication, which may interfere
             with contact lens wear. This may include, but not be limited to, diabetes,
             hyperthyroidism, recurrent herpes simplex/zoster, Sjögren's syndrome, xerophthalmia,
             acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any
             infectious diseases (e.g., hepatitis, tuberculosis).

          -  Use of any of the following medications within 1 week prior to enrollment: oral
             retinoid isotretinoin (e.g., Accutane), oral tetracyclines, topical scopolamine, oral
             phenothiazines (e.g. Haldol, Mellaril, Thorazine, Elavil, Pamelor, Compazine), oral
             and ophthalmic Beta-adrenergic blockers (e.g., Propranolol, Timolol, and Practolol),
             systemic steroids, and any prescribed or OTC ocular medication.

          -  Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of
             recurrent corneal erosions, aphakia, or moderate or above corneal distortion.

          -  Any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy,
             photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK),
             etc.)

          -  Any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization,
             corneal staining, tarsal abnormalities, conjunctival injection) on the FDA
             classification scale, any previous history or signs of a contact lens-related corneal
             inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any
             other ocular abnormality that may contraindicate contact lens wear.

          -  Any known hypersensitivity or allergic reaction to Opti-Free® PureMoist® multipurpose
             care solution or Eye-Cept rewetting drop solution

          -  Any ocular infection, allergy or clinically significant ocular disease (e.g., corneal
             edema, uveitis, severe keratoconjunctivitis sicca, ocular hypertension), or ocular
             conditions (e.g. strabismus), which might interfere with the study.

          -  Any corneal distortion resulting from previous hard or rigid gas permeable contact
             lens wear.

          -  Daily disposables, extended wear, monovision or multi-focal contact lens correction.

          -  History of binocular vision abnormality or strabismus.

          -  Employee or relative of employees of sponsor or investigational clinic (e.g.,
             Investigator, Coordinator, Technician)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vue Optical Boutique</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Vision Center, PA / Sabal Eye Care</name>
      <address>
        <city>Longwood</city>
        <state>Florida</state>
        <zip>32779</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eyecare Associates</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Debbie H. Kim, OD</name>
      <address>
        <city>Closter</city>
        <state>New Jersey</state>
        <zip>07624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacco Eye Group</name>
      <address>
        <city>Vestal</city>
        <state>New York</state>
        <zip>13850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. William Bogus</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>December 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2015</study_first_posted>
  <results_first_submitted>April 4, 2017</results_first_submitted>
  <results_first_submitted_qc>May 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2017</results_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vision Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 105 subjects were enrolled into this study. Of the enrolled subjects all were dispensed a study lens. Out of all the dispensed subjects 103 completed the study while 2 subjects were discontinued.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Senofilcon C</title>
          <description>Subjects that wore the senofilcon C lens throughout the entire duration of the study.</description>
        </group>
        <group group_id="P2">
          <title>Comfilcon A</title>
          <description>Subjects that wore the comfilcon A lens throughout the entire duration of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects that were enrolled into the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Senofilcon C</title>
          <description>Subjects that wore the senofilcon C lens throughout the entire duration of the study.</description>
        </group>
        <group group_id="B2">
          <title>Comfilcon A</title>
          <description>Subjects that wore the comfilcon A lens throughout the entire duration of the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.2" spread="7.03"/>
                    <measurement group_id="B2" value="31.5" spread="7.31"/>
                    <measurement group_id="B3" value="31.4" spread="7.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Eyes Grade 3 or Higher SLF</title>
        <description>Slit lamp findings were graded using a FDA Grade Scale, 0 = None, 1 = Slight, 2 = Moderate, 3 = Significant, 4 = Advanced. Measurements were taken in each subject eye at the initial visit, 4 month, 5 month and 6 month follow-up evaluations. This study is a continuation of a previous study therefore data from the initial visit was included in reporting. The proportion of subject eyes with SLF grade 3 or higher was reported for each lens.</description>
        <time_frame>Up to 6 Month Follow-up</time_frame>
        <population>Subjects that were dispensed a study lens.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon C</title>
            <description>Subjects that wore the senofilcon C lens througout the entire duration of the study.</description>
          </group>
          <group group_id="O2">
            <title>Comfilcon A</title>
            <description>Subjects that wore the comfilcon A lens throughout the entire duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Eyes Grade 3 or Higher SLF</title>
          <description>Slit lamp findings were graded using a FDA Grade Scale, 0 = None, 1 = Slight, 2 = Moderate, 3 = Significant, 4 = Advanced. Measurements were taken in each subject eye at the initial visit, 4 month, 5 month and 6 month follow-up evaluations. This study is a continuation of a previous study therefore data from the initial visit was included in reporting. The proportion of subject eyes with SLF grade 3 or higher was reported for each lens.</description>
          <population>Subjects that were dispensed a study lens.</population>
          <units>Proporiton of Subject Eyes</units>
          <param>Number</param>
          <units_analyzed>Subject Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Subject Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="448"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity (logMAR)</title>
        <description>The visual acuity (LogMAR) was collected at the initial visit, 4 month, 5 month and 6 month follow-up evaluations. This study is a continuation of a previous study therefore data from the initial visit was included in reporting. The average Visual Acuity (logMAR) across the 4 study visits and at each individual visit was reported for each lens.</description>
        <time_frame>Up to 6 Month Follow-up</time_frame>
        <population>Subjects that completed all study visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon C</title>
            <description>Subjects that wore the senofilcon C lens througout the entire duration of the study.</description>
          </group>
          <group group_id="O2">
            <title>Comfilcon A</title>
            <description>Subjects that wore the comfilcon A lens throughout the entire duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity (logMAR)</title>
          <description>The visual acuity (LogMAR) was collected at the initial visit, 4 month, 5 month and 6 month follow-up evaluations. This study is a continuation of a previous study therefore data from the initial visit was included in reporting. The average Visual Acuity (logMAR) across the 4 study visits and at each individual visit was reported for each lens.</description>
          <population>Subjects that completed all study visits.</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Subject Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Subject Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="448"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall N=376, N=448</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.066"/>
                    <measurement group_id="O2" value="-0.12" spread="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial Visit N=94, N=112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.069"/>
                    <measurement group_id="O2" value="-0.13" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Month Follow-up N=94, N=112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.069"/>
                    <measurement group_id="O2" value="-0.13" spread="0.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Month Follow-up N=94, N=112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.068"/>
                    <measurement group_id="O2" value="-0.12" spread="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month Follow-up N=94, N=112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.063"/>
                    <measurement group_id="O2" value="-0.13" spread="0.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throught the duration of the study. Approximately 3 months per subject.</time_frame>
      <desc>NCT02625233 is a continuation of NCT02515994. Each study was approximately 3 months duration for each subject(i.e. if a subject was enrolled into both studies they wore the lens a total of 6 months). Refer to the adverse event information for study NCT02515994 for the previous 3 months.</desc>
      <group_list>
        <group group_id="E1">
          <title>Senofilcon C</title>
          <description>Subjects that wore the senofilcon C lens throughout the entire duration of the study.</description>
        </group>
        <group group_id="E2">
          <title>Comfilcon A</title>
          <description>Subjects that wore the comfilcon A lens throughout the entire duration of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kristy Canavan, O.D., FAAO Principal Research Optometrist</name_or_title>
      <organization>Johson &amp; Johnson Vision Care Inc.</organization>
      <phone>904 443-1474</phone>
      <email>KCANAVA2@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

